SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 460
AS - Asia 157
EU - Europa 42
SA - Sud America 2
Totale 661
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 459
CN - Cina 100
SG - Singapore 42
IT - Italia 29
ID - Indonesia 8
BR - Brasile 2
FI - Finlandia 2
FR - Francia 2
HK - Hong Kong 2
LT - Lituania 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
CA - Canada 1
CZ - Repubblica Ceca 1
DE - Germania 1
EE - Estonia 1
GB - Regno Unito 1
IE - Irlanda 1
JO - Giordania 1
KG - Kirghizistan 1
NL - Olanda 1
PH - Filippine 1
PT - Portogallo 1
Totale 661
Salva come PNG Salva come JPEG
Città #
Santa Clara 400
Singapore 28
Bologna 8
Jakarta 8
Ashburn 5
Forest City 5
Ferrara 4
Los Angeles 4
Frattamaggiore 3
Arezzo 2
Brasília 2
Fort Worth 2
Hong Kong 2
Imola 2
Lappeenranta 2
Paris 2
Prineville 2
Salerno 2
Sandston 2
Springfield 2
Amman 1
Bishkek 1
Dhaka 1
Dublin 1
Frankfurt am Main 1
Lisbon 1
London 1
Manila 1
Napa 1
Naples 1
Ottawa 1
Parma 1
Prague 1
Tallinn 1
Volla 1
Totale 502
Salva come PNG Salva come JPEG
Nome #
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 17
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 17
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 16
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients 15
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 15
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 13
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 12
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 12
Anti-endothelin drugs in solid tumors 11
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 11
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 11
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 11
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 11
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 11
Bortezomib: A new pro-apoptotic agent in cancer treatment 11
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 11
A headlight on liquid biopsies: a challenging tool for breast cancer management 10
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 10
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 9
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 9
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 9
Cancer and the microbiome: Potential applications as new tumor biomarker 9
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 9
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 9
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 9
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 9
Well-being among Italian medical oncologists: An exploratory study 9
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 9
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 9
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 8
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 8
Petals and thorns in programmed death-ligand 1 testing: Is all non–small cell lung cancer diagnostic material suitable? 8
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 7
The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review 7
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 7
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 7
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 7
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 7
Monoclonal antibodies in gastrointestinal cancers 7
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 7
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 7
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 7
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 7
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 7
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 7
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 7
Ramucirumab and its use in gastric cancer treatment 7
DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes 7
New generation anaplastic lymphoma kinase inhibitors 6
Management of toxicity induced by anti-EGFR therapy in metastatic colorectal cancer 6
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 6
Multisciplinary management of patients with liver metastasis from colorectal cancer 6
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 6
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 6
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 6
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 6
Targeted therapies in hepatocellular carcinoma 6
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors 6
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 6
How much of familial breast cancer risk is currently explained by the known genes? 6
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 6
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 6
TMB in NSCLC: A Broken Dream? 6
Predicting efficacy and toxicity in the era of targeted therapy: Focus on anti-EGFR and anti-VEGF molecules 6
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 6
The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies 6
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 6
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 6
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 6
Fully human antibodies for malignant pleural mesothelioma targeting 6
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 6
What to look for in cell-free DNA from breast cancer patients 6
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 6
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 6
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 6
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 6
Dietary restriction: could it be considered as speed bump on tumor progression road? 6
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 6
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 6
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 6
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 6
Relationship between imaging‐derived parameters and circulating microRNAs to study the degree of lung involvement in hospitalized geriatric patients with COVID‐19 pneumonia 6
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 6
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 6
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects 6
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 6
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines 6
Magnetic Resonance Imaging and 99Tc WBC-SPECT/CT Scanning in Differential Diagnosis between Osteomyelitis and Charcot Neuroarthropathy: A Case Series 6
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 6
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 6
Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors 6
Sex steroids, carcinogenesis, and cancer progression 6
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 6
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 6
Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy 6
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer 6
Nintedanib in NSCLC: Evidence to date and place in therapy 6
The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer 6
Immunotherapy for recurrent ovarian cancer: A further piece of the puzzle or a striking strategy? 6
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases 6
Totale 772
Salva come PNG Salva come JPEG
Categoria #
all - tutte 6.950
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 6.950
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024157 0 0 0 0 0 0 0 4 21 3 11 118
2024/2025632 38 100 32 19 204 239 0 0 0 0 0 0
Totale 789